Indian Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 72 Business Hours
Indian Clinical Trials Market Growth & Trends
The Indian clinical trials market size is expected to reach USD 3.88 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.2% from 2022 to 2030. The globalization of clinical trials, growing disease variation and prevalence in the country, adoption of new technology in clinical research, and increasing R&D promoting outsourcing are the key factors driving the market.
India is populated with 1.3 billion individuals with varying genetic backgrounds and a large treatment-na?ve patient pool for the development of therapeutics on a range of disease conditions. Furthermore, the economic, environmental, and ecological variations in the 28 states and 8 union territories present the most diverse disease profile. Apart from this, the cost of carrying out clinical trials in India is nearly 40-70% less when compared to that in Europe or the U.S. Thus, the cost efficiency, along with skill sets and ease of doing business, is anticipated to fuel the market growth.
The increasing R&D investments by pharmaceutical and biopharmaceutical companies have led to increased demand for contract research organizations and outsourcing of trials in order to curb the cost. Furthermore, outsourcing enables the drug companies to focus on their core competencies and aids in improving their productivity, thus facilitating the outsourcing of trials in India. The COVID-19 pandemic has improved the market in the country. Several companies globally are conducting clinical trials for COVID-19 vaccines in India. Moreover, government initiatives promoting clinical trials for COVID-19 therapeutics in the country have promoted market growth.
Indian Clinical Trials Market Report Highlights
Indian Clinical Trials Market Growth & Trends
The Indian clinical trials market size is expected to reach USD 3.88 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.2% from 2022 to 2030. The globalization of clinical trials, growing disease variation and prevalence in the country, adoption of new technology in clinical research, and increasing R&D promoting outsourcing are the key factors driving the market.
India is populated with 1.3 billion individuals with varying genetic backgrounds and a large treatment-na?ve patient pool for the development of therapeutics on a range of disease conditions. Furthermore, the economic, environmental, and ecological variations in the 28 states and 8 union territories present the most diverse disease profile. Apart from this, the cost of carrying out clinical trials in India is nearly 40-70% less when compared to that in Europe or the U.S. Thus, the cost efficiency, along with skill sets and ease of doing business, is anticipated to fuel the market growth.
The increasing R&D investments by pharmaceutical and biopharmaceutical companies have led to increased demand for contract research organizations and outsourcing of trials in order to curb the cost. Furthermore, outsourcing enables the drug companies to focus on their core competencies and aids in improving their productivity, thus facilitating the outsourcing of trials in India. The COVID-19 pandemic has improved the market in the country. Several companies globally are conducting clinical trials for COVID-19 vaccines in India. Moreover, government initiatives promoting clinical trials for COVID-19 therapeutics in the country have promoted market growth.
Indian Clinical Trials Market Report Highlights
- By phase, the phase I segment is projected to register the fastest growth rate of 9.9% over the forecast period. This can be attributed to the increasing R&D spending by pharmaceutical and biopharmaceutical companies
- The interventional trials study design segment held the largest revenue share of over 40.0% in 2021 owing to the greater accuracy offered by them as compared to observational study design
- The oncology indication segment held the largest revenue share of over 20.0% in 2021 due to the increasing prevalence of the disease condition and the consequent rise in demand for innovative therapies for cancer
CHAPTER 1 REPORT SCOPE
1.1 Phase
1.2 Study Design
1.3 Indication
1.4 Estimates and Forecast Timeline
CHAPTER 2 METHODOLOGY
2.1 Research Methodology
2.1.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
2.4 Region Share Calculation
2.5 List of Secondary Sources
2.6 List of Primary Sources
2.7 List of Abbreviations
CHAPTER 3 EXECUTIVE SUMMARY
3.1 Market Snapshot
CHAPTER 4 INDUSTRY OUTLOOK
4.1 Market Segmentation
4.2 Business Segment Trends
4.3 Market Variable Analysis
4.3.1 Market Driver Analysis
4.3.1.1 Globalization Of Clinical Trials
4.3.1.2 Adoption Of New Technology In Clinical Research
4.3.1.3 Growing Disease Variationnd Prevalence
4.3.1.4 Increasing Research And Development Promoting Outsourcing
4.3.2 Market Restraint Analysis
4.3.2.1 Pricing Pressure
4.3.2.2 Regulatory Issues.
4.4 Penetration & Growth Prospect Mapping
4.5 Business Environment Analysis tools
4.5.1 Swot Analysis, By Pest
4.5.2 Porter’s five forces analysis
4.5.3 Clinical Trial Registry.
4.5.4 The Objective Of The Registry
4.5.5 Future Prospects
4.5.6 Clinical Trial Registration Process Flow.
CHAPTER 5 PHASE ESTIMATES AND TREND ANALYSIS
5.1 Indian Clinical Trials Market: Phase Movement Analysis
5.2 Phase I
5.2.1 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
5.3 Phase II
5.3.1 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
5.4 Phase III
5.4.1 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
5.5 Phase IV
5.5.1 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 6 STUDY DESIGN ESTIMATES AND TREND ANALYSIS
6.1 Indian Clinical Trials Market: Study Design Movement Analysis
6.2 Interventional trials
6.2.1 Interventional trials market estimates and forecast, 2018 - 2030 (USD Million)
6.3 Observational trials
6.3.1 Observational trials market estimates and forecast, 2018 - 2030 (USD Million)
6.4 Expanded access trials
6.4.1 Expanded access trials market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 7 INDICATION ESTIMATES AND TREND ANALYSIS
7.1 Indian Clinical Trials Market: Indication Movement Analysis
7.2 Autoimmune/inflammation
7.2.1 Autoimmune/inflammation market estimates and forecast, 2018 - 2030 (USD Million)
7.2.2 Rheumatoid arthritis
7.2.3 rheumatoid arthritis market estimates and forecast, 2018 - 2030 (USD Million)
7.2.4 Multiple sclerosis
7.2.5 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
7.2.6 Osteoarthritis
7.2.7 Osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
7.2.8 Irritable Bowel Syndrome (IBS)
7.2.9 Irritable Bowel Syndrome (IBS) market estimates and forecast, 2018 - 2030 (USD Million)
7.2.10 Others
7.2.11 others market estimates and forecast, 2018 - 2030 (USD Million)
7.3 Pain management
7.3.1 pain management market estimates and forecast, 2018 - 2030 (USD Million)
7.3.2 Chronic pain
7.3.3 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
7.3.4 Acute pain
7.3.5 Acute pain market estimates and forecast, 2018 - 2030 (USD Million)
7.4 Oncology
7.4.1 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2 Blood cancer
7.4.3 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.4.4 Solid tumors
7.4.5 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
7.4.6 Other
7.4.7 Other market estimates and forecast, 2018 - 2030 (USD Million)
7.5 CNS Conditions
7.5.1 CNS conditions market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2 Epilepsy
7.5.3 Epilepsy market estimates and forecast, 2018 - 2030 (USD Million)
7.5.4 Parkinson's Disease (PD)
7.5.5 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
7.5.6 Huntington's Disease
7.5.7 Huntington's disease market estimates and forecast, 2018 - 2030 (USD Million)
7.5.8 Stroke
7.5.9 Stroke market estimates and forecast, 2018 - 2030 (USD Million)
7.5.10 Traumatic Brain Injury (TBI)
7.5.11 Traumatic Brain Injury (TBI) market estimates and forecast, 2018 - 2030 (USD Million)
7.5.12 Amyotrophic Lateral Sclerosis (ALS)
7.5.13 Amyotrophic Lateral Sclerosis (ALS) market estimates and forecast, 2018 - 2030 (USD Million)
7.5.14 Muscle regeneration
7.5.15 Muscle regeneration market estimates and forecast, 2018 - 2030 (USD million)
7.5.16 Others
7.5.17 Others market estimates and forecast, 2018 - 2030 (USD Million)
7.6 Diabetes
7.6.1 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
7.7 Obesity
7.7.1 Obesity market estimates and forecast, 2018 - 2030 (USD Million)
7.8 Cardiovascular
7.8.1 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
7.9 Others
7.9.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 8 COMPANY PROFILES
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 IQVIA holdings Inc. (QUintilesIMS)
8.2.1.1 Company Overview
8.2.1.2 Financial Performance
8.2.1.3 Product Benchmarking
8.2.1.4 Strategic Initiatives
8.2.1.5 SWOT Analysis
8.2.2 Paraxel International Corporation
8.2.2.1 Company Overview
8.2.2.2 Financial Performance
8.2.2.3 Product Benchmarking
8.2.2.4 Strategic Initiatives
8.2.2.5 SWOT Analysis
8.2.3 Pharmaceutical Product Development, LLC
8.2.3.1 Company Overview
8.2.3.2 Financial Performance
8.2.3.3 Product Benchmarking
8.2.3.4 Strategic Initiatives
8.2.3.5 SWOT Analysis
8.2.4 Charles River Laboratory
8.2.4.1 Company Overview
8.2.4.2 Financial Performance
8.2.4.3 Product Benchmarking
8.2.4.4 Strategic Initiatives
8.2.4.5 SWOT Analysis
8.2.5 ICON plc
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Product Benchmarking
8.2.5.4 Strategic Initiatives
8.2.5.5 SWOT Analysis
8.2.6 PRA Health Sciences, INC.
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Product Benchmarking
8.2.6.4 Strategic Initiatives
8.2.6.5 SWOT Analysis
8.2.7 Chiltern International Ltd. (Covance Inc.)
8.2.7.1 Company Overview
8.2.7.2 Financial Performance
8.2.7.3 Product Benchmarking
8.2.7.4 Strategic Initiatives
8.2.7.5 SWOT Analysis
8.2.8 Syneos Health Inc. (inc research)
8.2.8.1 Company Overview
8.2.8.2 Financial Performance
8.2.8.3 Product Benchmarking
8.2.8.4 Strategic Initiatives.
8.2.8.5 SWOT Analysis
8.2.9 SGS SA
8.2.9.1 Company Overview
8.2.9.2 Financial Performance
8.2.9.3 Product Benchmarking
8.2.9.4 Strategic Initiatives
8.2.9.5 SWOT Analysis
8.2.10 Syngene International Limited
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Product Benchmarking
8.2.10.4 Strategic Initiatives
8.2.10.5 SWOT Analysis
8.2.11 Aurigene Discovery Technologies Limited
8.2.11.1 Company Overview
8.2.11.2 Financial Performance
8.2.11.3 Product Benchmarking
8.2.11.4 Strategic Initiatives
8.2.11.5 SWOT Analysis
8.2.12 Aragen Life Sciences
8.2.12.1 Company Overview
8.2.12.2 Financial Performance
8.2.12.3 Product Benchmarking
8.2.12.4 Strategic Initiatives
8.2.12.5 SWOT Analysis
1.1 Phase
1.2 Study Design
1.3 Indication
1.4 Estimates and Forecast Timeline
CHAPTER 2 METHODOLOGY
2.1 Research Methodology
2.1.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
2.4 Region Share Calculation
2.5 List of Secondary Sources
2.6 List of Primary Sources
2.7 List of Abbreviations
CHAPTER 3 EXECUTIVE SUMMARY
3.1 Market Snapshot
CHAPTER 4 INDUSTRY OUTLOOK
4.1 Market Segmentation
4.2 Business Segment Trends
4.3 Market Variable Analysis
4.3.1 Market Driver Analysis
4.3.1.1 Globalization Of Clinical Trials
4.3.1.2 Adoption Of New Technology In Clinical Research
4.3.1.3 Growing Disease Variationnd Prevalence
4.3.1.4 Increasing Research And Development Promoting Outsourcing
4.3.2 Market Restraint Analysis
4.3.2.1 Pricing Pressure
4.3.2.2 Regulatory Issues.
4.4 Penetration & Growth Prospect Mapping
4.5 Business Environment Analysis tools
4.5.1 Swot Analysis, By Pest
4.5.2 Porter’s five forces analysis
4.5.3 Clinical Trial Registry.
4.5.4 The Objective Of The Registry
4.5.5 Future Prospects
4.5.6 Clinical Trial Registration Process Flow.
CHAPTER 5 PHASE ESTIMATES AND TREND ANALYSIS
5.1 Indian Clinical Trials Market: Phase Movement Analysis
5.2 Phase I
5.2.1 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
5.3 Phase II
5.3.1 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
5.4 Phase III
5.4.1 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
5.5 Phase IV
5.5.1 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 6 STUDY DESIGN ESTIMATES AND TREND ANALYSIS
6.1 Indian Clinical Trials Market: Study Design Movement Analysis
6.2 Interventional trials
6.2.1 Interventional trials market estimates and forecast, 2018 - 2030 (USD Million)
6.3 Observational trials
6.3.1 Observational trials market estimates and forecast, 2018 - 2030 (USD Million)
6.4 Expanded access trials
6.4.1 Expanded access trials market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 7 INDICATION ESTIMATES AND TREND ANALYSIS
7.1 Indian Clinical Trials Market: Indication Movement Analysis
7.2 Autoimmune/inflammation
7.2.1 Autoimmune/inflammation market estimates and forecast, 2018 - 2030 (USD Million)
7.2.2 Rheumatoid arthritis
7.2.3 rheumatoid arthritis market estimates and forecast, 2018 - 2030 (USD Million)
7.2.4 Multiple sclerosis
7.2.5 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
7.2.6 Osteoarthritis
7.2.7 Osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
7.2.8 Irritable Bowel Syndrome (IBS)
7.2.9 Irritable Bowel Syndrome (IBS) market estimates and forecast, 2018 - 2030 (USD Million)
7.2.10 Others
7.2.11 others market estimates and forecast, 2018 - 2030 (USD Million)
7.3 Pain management
7.3.1 pain management market estimates and forecast, 2018 - 2030 (USD Million)
7.3.2 Chronic pain
7.3.3 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
7.3.4 Acute pain
7.3.5 Acute pain market estimates and forecast, 2018 - 2030 (USD Million)
7.4 Oncology
7.4.1 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2 Blood cancer
7.4.3 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.4.4 Solid tumors
7.4.5 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
7.4.6 Other
7.4.7 Other market estimates and forecast, 2018 - 2030 (USD Million)
7.5 CNS Conditions
7.5.1 CNS conditions market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2 Epilepsy
7.5.3 Epilepsy market estimates and forecast, 2018 - 2030 (USD Million)
7.5.4 Parkinson's Disease (PD)
7.5.5 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
7.5.6 Huntington's Disease
7.5.7 Huntington's disease market estimates and forecast, 2018 - 2030 (USD Million)
7.5.8 Stroke
7.5.9 Stroke market estimates and forecast, 2018 - 2030 (USD Million)
7.5.10 Traumatic Brain Injury (TBI)
7.5.11 Traumatic Brain Injury (TBI) market estimates and forecast, 2018 - 2030 (USD Million)
7.5.12 Amyotrophic Lateral Sclerosis (ALS)
7.5.13 Amyotrophic Lateral Sclerosis (ALS) market estimates and forecast, 2018 - 2030 (USD Million)
7.5.14 Muscle regeneration
7.5.15 Muscle regeneration market estimates and forecast, 2018 - 2030 (USD million)
7.5.16 Others
7.5.17 Others market estimates and forecast, 2018 - 2030 (USD Million)
7.6 Diabetes
7.6.1 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
7.7 Obesity
7.7.1 Obesity market estimates and forecast, 2018 - 2030 (USD Million)
7.8 Cardiovascular
7.8.1 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
7.9 Others
7.9.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 8 COMPANY PROFILES
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 IQVIA holdings Inc. (QUintilesIMS)
8.2.1.1 Company Overview
8.2.1.2 Financial Performance
8.2.1.3 Product Benchmarking
8.2.1.4 Strategic Initiatives
8.2.1.5 SWOT Analysis
8.2.2 Paraxel International Corporation
8.2.2.1 Company Overview
8.2.2.2 Financial Performance
8.2.2.3 Product Benchmarking
8.2.2.4 Strategic Initiatives
8.2.2.5 SWOT Analysis
8.2.3 Pharmaceutical Product Development, LLC
8.2.3.1 Company Overview
8.2.3.2 Financial Performance
8.2.3.3 Product Benchmarking
8.2.3.4 Strategic Initiatives
8.2.3.5 SWOT Analysis
8.2.4 Charles River Laboratory
8.2.4.1 Company Overview
8.2.4.2 Financial Performance
8.2.4.3 Product Benchmarking
8.2.4.4 Strategic Initiatives
8.2.4.5 SWOT Analysis
8.2.5 ICON plc
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Product Benchmarking
8.2.5.4 Strategic Initiatives
8.2.5.5 SWOT Analysis
8.2.6 PRA Health Sciences, INC.
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Product Benchmarking
8.2.6.4 Strategic Initiatives
8.2.6.5 SWOT Analysis
8.2.7 Chiltern International Ltd. (Covance Inc.)
8.2.7.1 Company Overview
8.2.7.2 Financial Performance
8.2.7.3 Product Benchmarking
8.2.7.4 Strategic Initiatives
8.2.7.5 SWOT Analysis
8.2.8 Syneos Health Inc. (inc research)
8.2.8.1 Company Overview
8.2.8.2 Financial Performance
8.2.8.3 Product Benchmarking
8.2.8.4 Strategic Initiatives.
8.2.8.5 SWOT Analysis
8.2.9 SGS SA
8.2.9.1 Company Overview
8.2.9.2 Financial Performance
8.2.9.3 Product Benchmarking
8.2.9.4 Strategic Initiatives
8.2.9.5 SWOT Analysis
8.2.10 Syngene International Limited
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Product Benchmarking
8.2.10.4 Strategic Initiatives
8.2.10.5 SWOT Analysis
8.2.11 Aurigene Discovery Technologies Limited
8.2.11.1 Company Overview
8.2.11.2 Financial Performance
8.2.11.3 Product Benchmarking
8.2.11.4 Strategic Initiatives
8.2.11.5 SWOT Analysis
8.2.12 Aragen Life Sciences
8.2.12.1 Company Overview
8.2.12.2 Financial Performance
8.2.12.3 Product Benchmarking
8.2.12.4 Strategic Initiatives
8.2.12.5 SWOT Analysis
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 India Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 4 India Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 5 India Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 India Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 4 India Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 5 India Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Indian clinical trials market summary
Fig. 9 Indian clinical trials market segmentation
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Phase wise clinical studies conducted in 2021
Fig. 16 Number of clinical trials conducted over the years in India
Fig. 17 Clinical trial registration process flow
Fig. 18 Indian clinical trials market phase outlook: Key takeaways
Fig. 19 Indian clinical trials market: Phase movement analysis
Fig. 20 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Indian clinical trials market study design outlook: Key takeaways
Fig. 25 Indian clinical trials market: study design movement analysis
Fig. 26 Interventional trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Observational trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Expanded access trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Indian clinical trials market indication outlook: Key takeaways
Fig. 30 Indian clinical trials market: indication movement analysis
Fig. 31 Autoimmune/inflammation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Rheumatoid arthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Irritable Bowel Syndrome (IBS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Pain management market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Acute pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 CNS Conditions market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Epilepsy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Parkinson's Disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Huntington's Disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Stroke market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Traumatic Brain Injury (TBI) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Amyotrophic Lateral Sclerosis (ALS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Muscle regeneration market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Obesity market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Strategy framework
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Indian clinical trials market summary
Fig. 9 Indian clinical trials market segmentation
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Phase wise clinical studies conducted in 2021
Fig. 16 Number of clinical trials conducted over the years in India
Fig. 17 Clinical trial registration process flow
Fig. 18 Indian clinical trials market phase outlook: Key takeaways
Fig. 19 Indian clinical trials market: Phase movement analysis
Fig. 20 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Indian clinical trials market study design outlook: Key takeaways
Fig. 25 Indian clinical trials market: study design movement analysis
Fig. 26 Interventional trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Observational trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Expanded access trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Indian clinical trials market indication outlook: Key takeaways
Fig. 30 Indian clinical trials market: indication movement analysis
Fig. 31 Autoimmune/inflammation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Rheumatoid arthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Irritable Bowel Syndrome (IBS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Pain management market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Acute pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 CNS Conditions market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Epilepsy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Parkinson's Disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Huntington's Disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Stroke market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Traumatic Brain Injury (TBI) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Amyotrophic Lateral Sclerosis (ALS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Muscle regeneration market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Obesity market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Strategy framework
